NUVB:NYE-Nuvation Bio Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.8

Change

0.00 (0.00)%

Market Cap

USD 1.03B

Volume

2.39M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 609.93B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.82B
RCUS Arcus Biosciences Inc

N/A

USD 1.64B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.35B
ADCT ADC Therapeutics SA

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.15B
ANVS Annovis Bio Inc

N/A

USD 0.11B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B
CVM CEL-SCI Corp

N/A

USD 0.08B

ETFs Containing NUVB

CNCR Loncar Cancer Immunothera.. 1.81 % 0.79 %

N/A

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 85.43% 91% A- 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.43% 91% A- 99% N/A
Trailing 12 Months  
Capital Gain 110.53% 91% A- 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 110.53% 91% A- 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -19.35% 27% F 4% F
Dividend Return -19.35% 27% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.39% 61% D- 18% F
Risk Adjusted Return -38.40% 27% F 8% B-
Market Capitalization 1.03B 89% A- 57% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.